Angiodynamics Inc: Form 10-Q for the period ended Feb 28, 2017
Filed with the SEC on Apr 3, 2017 and accepted by EDGAR at Apr 3, 2017, 10:55 ET.
Management's discussion and analysis
As filed, 26,545 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following information should be read together with the consolidated condensed financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.
Forward-Looking Statements
This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC.
Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.
Executive Overview
We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or longer-term use.
Our sales and profitability growth depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products. Expansions to our product offerings are created through internal product development, technology licensing and strategic alliances. In recent years we have acquired or developed, and launched several new products, including the AngioVac cannula and circuit, the BioFlo family of products, NanoKnife and the Acculis microwave system, which are all currently contributing to our revenue profile. We obtained CE Mark certification for the Solero microwave thermal ablation system at the end of the third quarter. We recognize the importance of, and intend to continue to make investments in, research and development activities and business development opportunities and feel confident that our existing capital structure and free cash flow generation will allow us to properly fund those activities.
We sell our products in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. We expect our businesses to grow in both sales and profit through geographic expansion, market penetration, new product introductions and increasing our direct presence internationally.
The following financial metrics will assist in evaluating the operating performance of our business for the three and nine months ended February 28, 2017 compared to the three and nine months ended February 29, 2016:
Three months ended February 28, 2017
- Reported revenue decreased by 2.1% to $85.6 million
- Constant currency revenue decreased by 1.9%
- Operating income increased by $3.2 million to $5.1 million
- Diluted earnings per share increased by $0.06 to $0.08
Nine months ended February 28, 2017
- Reported revenue increased by 0.9% to $262.7 million
- Constant currency revenue increased by 1.1%
- Operating income increased by $21.6 million to $24.3 million
- Diluted earnings per share increased by $0.49 to $0.48
- Cash flow from operations increased by $10.1 million to $36.8 million
For our third quarter results, revenue across the business was soft offset partially by growth in the Oncology franchise as a result of the launch of our thermal ablation product in Japan. It was also offset slightly by continued growth in our core product line along with solid performance of BioFlo in both Midlines and Dialysis. The increase in operating income was driven primarily by continued focus on operational excellence in the plant and cost management actions in operating expenses.
Management's Use of Non-GAAP Measures
Net sales “on a constant currency basis” is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the Company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company’s investors. Constant currency growth rates are calculated by subtracting the current period's local currency sales at the prior period’s exchange rate from the current period’s local currency sales at the current period’s exchange rate.
Constant currency growth rates are not indicative of changes in corresponding cash flows. The limitation of these non-GAAP measures is that they do not reflect results on a standardized reporting basis. Non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be viewed as replacements of GAAP results.
New Accounting Pronouncements
Information regarding new accounting pronouncements is included in Note P to our consolidated condensed financial statements in this Quarterly Report on Form 10-Q.
Results of Operations for the Three Months ended February 28, 2017 and February 29, 2016
For the three months ended February 28, 2017, we reported net income of $2.9 million, or $0.08 per diluted share, on net sales of $85.6 million, compared with a net income of $0.6 million, or $0.02 per share, on net sales of $87.4 million during the same quarter of the prior year.
Net Sales
Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.
Net sales for the three months ended February 28, 2017 and February 29, 2016:
| Net Sales by Product Category | Three months ended Feb 28, 2017 | Feb 29, 2016 | % Growth | Currency Impact (Pos) Neg | Constant Currency |
|---|---|---|---|---|---|
| Peripheral Vascular | $48,496 | $49,779 | (3)% | ||
| Vascular Access | 23,680 | 24,911 | (5)% | ||
| Oncology/Surgery | 12,993 | 12,054 | 8% | ||
| Total Excluding Supply Agreement | 85,169 | 86,744 | (2)% | —% | (2)% |
| Supply Agreement | 433 | 690 | (37)% | —% | (37)% |
| Total | $85,602 | $87,434 | (2)% | —% | (2)% |
| Net Sales by Geography | |||||
| United States | $67,366 | $69,501 | (3)% | —% | (3)% |
| International | 17,803 | 17,243 | 3% | 1% | 4% |
| Supply Agreement | 433 | 690 | (37)% | —% | (37)% |
| Total | $85,602 | $87,434 | (2)% | —% | (2)% |
For the three months ended February 28, 2017, net sales decreased $1.8 million to $85.6 million compared to the same period in the prior year.
From a product line perspective, Peripheral Vascular sales decreased 3% primarily attributable to softness in our fluid management and venous businesses offset slightly by increased volume in our core business. Vascular Access sales decreased 5% due to softness in PICCs and ports offset by continued strength in our Midlines and Bioflo Dialysis products. Oncology Surgery sales increased 8% due to the launch of our thermal ablation product in Japan and utilization across all product lines.
From a geographic perspective, U.S. sales decreased 3% primarily due to increasing pricing pressures and competition in our Peripheral Vascular and Vascular Access businesses. International sales increased 4% on a constant-currency basis, primarily attributable to the launch of our thermal ablation product in the Japanese market and increased volume in BioFlo PICCs.
Gross Profit, Operating expenses, and Other income (expense)
| Three months ended Feb 28, 2017 | Feb 29, 2016 | % Change | |
|---|---|---|---|
| Gross profit | $43.8 | $43.5 | 1% |
| Gross profit % of sales | 51.2% | 49.8% | |
| Research and development | $6.0 | $5.8 | 3% |
| % of sales | 7.0% | 6.6% | |
| Selling and marketing | $19.5 | $21.0 | (7)% |
| % of sales | 22.7% | 24.0% | |
| General and administrative | $7.0 | $6.9 | 1% |
| % of sales | 8.2% | 7.9% | |
| Medical device excise tax | $— | $0.4 | (100)% |
| % of sales | —% | 0.5% |
Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Despite the revenue shortfall, gross profit was $0.3 million favorable versus prior year due to continued focus on operational excellence programs offset by pricing pressures globally, foreign currency impacts and mix of products compared to prior year compared to the three months ended February 29, 2016.
Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs. R&D expenses increased $0.2 million for the three months ending February 28, 2017 due to investments in regulatory headcount and registration costs ($0.6 million) partially offset by lower project spend ($0.4 million) related to implementation of a new product development process that is prioritizing project spend.
Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses decreased by $1.5 million for the three months ending February 28, 2017 due to sales and marketing roles that have not been filled and lower commissions ($0.4 million), lower bad debt expense ($0.6 million), reduced travel costs ($0.2 million) and samples management ($0.2 million).
General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses increased $0.1 million for the three months ended February 28, 2017 due to recruitment and relocation expense ($0.2 million) partially offset by improved benefit claim performance versus in the prior year ($0.1 million).
Medical device excise tax - Medical devices excise tax is assessed on our US product sales subject to exclusions and adjustments during the second quarters of fiscal 2016. The expense decreased for the three months ending February 28, 2017 compared to the prior year due to the suspension of the medical device excise tax as of the end of December 2015.
| Three months ended Feb 28, 2017 | Feb 29, 2016 | $ Change | |
|---|---|---|---|
| Amortization of intangibles | $4.4 | $4.5 | $(0.1) |
| Change in fair value of contingent consideration | $0.1 | $— | $0.1 |
| Acquisition, restructuring and other items, net | $1.8 | $3.0 | $(1.2) |
| Other expense | $(0.6) | $(1.0) | $0.4 |
Amortization of intangibles - Amortization of intangibles decreased from the three months ending February 28, 2017 to February 29, 2016 primarily due to intangibles that became fully amortized.
Change in fair value of contingent consideration - Represents changes in the contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration. The balance remained consistent with the prior year and consists of normal amortization.
Acquisition, restructuring and other items, net - Expense for the three months ended February 28, 2017 consists primarily of $0.2 million in severance related to the plant consolidation announced in February 2017 and $1.5 million in litigation expense. The three months ended February 29, 2016 included $0.3 million in accelerated depreciation, $1.5 million in litigation expense and other miscellaneous items.
Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs. The decrease in other expenses is primarily attributed to foreign currency remeasurement.
| Three months ended Feb 28, 2017 | Feb 29, 2016 | |
|---|---|---|
| Income tax expense (benefit) | $1.7 | $0.4 |
| Effective tax rate including discrete items | 36.6% | 37.1% |
Income taxes - Our effective tax rate including discrete items for the three month periods ended February 28, 2017 and February 29, 2016 was 36.6% and 37.1%, respectively. The change in the effective tax rate, detailed in Note G, is primarily driven by the impact of the US valuation allowance and the deferred tax liability related to intangibles that have an indefinite reversal period and cannot be used to support the deferred tax assets.
Results of Operations for the Nine Months ended February 28, 2017 and February 29, 2016
For the nine months ended February 28, 2017, we reported net income of $17.9 million, or $0.48 per diluted share, on net sales of $262.7 million, compared with a net loss of $0.5 million, or $(0.01) per share, on net sales of $260.5 million during the same quarter of the prior year.
Net Sales
Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns.
Net sales for the nine months ended February 28, 2017 and February 29, 2016:
| Net Sales by Product Category | Nine months ended Feb 28, 2017 | Feb 29, 2016 | % Growth | Currency Impact (Pos) Neg | Constant Currency |
|---|---|---|---|---|---|
| Peripheral Vascular | $152,800 | $147,940 | 3% | ||
| Vascular Access | 72,238 | 74,576 | (3)% | ||
| Oncology/Surgery | 35,837 | 35,859 | —% | ||
| Total Excluding Supply Agreement | 260,875 | 258,375 | 1% | —% | 1% |
| Supply Agreement | 1,854 | 2,096 | (12)% | —% | (12)% |
| Total | $262,729 | $260,471 | 1% | —% | 1% |
| Net Sales by Geography | |||||
| United States | $209,901 | $208,523 | 1% | —% | 1% |
| International | 50,974 | 49,852 | 2% | 2% | 4% |
| Supply Agreement | 1,854 | 2,096 | (12)% | —% | (12)% |
| Total | $262,729 | $260,471 | 1% | —% | 1% |
26
For the nine months ended February 28, 2017, net sales increased $2.3 million to $262.7 million compared to the same period in the prior year. As shown in the table above, consolidated net sales increased by 1% on a constant currency basis.
From a product line perspective, Peripheral Vascular sales increased 3% primarily attributable to increased volume in our Angiographic product line which is offsetting softness in other areas of the Peripheral Vascular business. Vascular Access sales decreased 3% due to softness in PICCS and ports offset by continued growth in our Midlines and BioFlo Dialysis product lines. Oncology Surgery sales were flat year over year.
From a geographic perspective, U.S. sales increased 1% due primarily to increased volume in the Angiographic product line, BioFlo Midlines and NanoKnife product lines. International sales increased 4% on a constant-currency basis, primarily attributable to growth in our Core, PICCs and Thermal Ablation product lines.
Gross Profit, Operating expenses, and Other income (expense)
| Nine months ended Feb 28, 2017 | Feb 29, 2016 | % Change | |
|---|---|---|---|
| Gross profit | $133.8 | $132.8 | 1% |
| Gross profit % of sales | 50.9% | 51.0% | |
| Research and development | $18.6 | $18.1 | 3% |
| % of sales | 7.1% | 7.0% | |
| Selling and marketing | $58.5 | $63.5 | (8)% |
| % of sales | 22.7% | 24.4% | |
| General and administrative | $23.0 | $22.9 | —% |
| % of sales | 8.7% | 8.8% | |
| Medical device excise tax | $— | $2.4 | (100)% |
| % of sales | —% | 0.9% |
Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. The $1.0 million increase for the nine months February 28, 2017 is primarily attributable to net productivity offset by pricing pressures globally, foreign currency impacts and mix of products compared to prior year.
Research and development expenses - Research and development (“R&D”) expenses include internal and external costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs. R&D expenses increased $0.5 million for the nine months ending February 28, 2017 due to increased headcount in regulatory and quality ($0.7 million), higher severance and bonus accrual ($0.7 million) offset by lower project spend related to implementation of a new product development process ($0.9 million).
Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses decreased by $5.0 million for the nine months ending February 28, 2017 due to open positions and commissions ($1.3 million), reduced travel costs ($1.4 million), depreciation expense ($0.4 million), and cost management on sales meetings and samples ($1.8 million).
General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses were flat for the nine months ended February 28, 2017, driven by increased stock based compensation expense ($1.0 million) and accounting fees ($0.5 million), offset by lower depreciation ($0.6 million) and benefits rate favorability ($1.2 million).
Medical device excise tax - Medical devices excise tax is assessed on our US product sales subject to exclusions and adjustments during the first two quarters of fiscal 2016. The expense decreased for the nine months ending February 28, 2017 compared to the prior year due to the suspension of the medical device excise tax as of the end of December 2015.
| Nine months ended Feb 28, 2017 | Feb 29, 2016 | $ Change | |
|---|---|---|---|
| Amortization of intangibles | $12.9 | $13.4 | $(0.5) |
| Change in fair value of contingent consideration | $(15.4) | $0.6 | $(16.0) |
| Acquisition, restructuring and other items, net | $12.0 | $9.1 | $2.9 |
| Other expense | $(2.4) | $(3.2) | $0.8 |
Amortization of intangibles - Amortization of intangibles decreased from the nine months ending February 28, 2017 to February 29, 2016 primarily due to intangibles that became fully amortized.
Change in fair value of contingent consideration - Represents changes in the contingent consideration driven by changes to estimated future payments on earn-out liabilities created through acquisitions and amortization of present value discounts on long-term contingent consideration. The decrease is due to a gain of $13.4 million that was taken on the AngioVac product as a result of decreases in future sales projections that eliminated any payments above minimums and a gain of $3.1 million on the TiLo product as the milestone will not be achieved. This was partially offset by normal amortization.
Acquisition, restructuring and other items, net - Expense for the nine months ended February 28, 2017 consists primarily of $1.0 million in severance, of which, $0.2 million relates to the plant consolidation, $5.2 million in litigation expense; $2.0 million for the write-off of Embomedics due to termination of the agreement and $3.6 million related to the decision to discontinue our investment in the TiLo product, as described above. The nine months ended February 29, 2016 included $1.0 million in accelerated depreciation, $5.4 million in litigation expense, $1.6 million in mergers and acquisition due diligence and $1.1 other miscellaneous items.
Other expenses - Other expenses include interest expense, foreign currency impacts, bank fees, and amortization of deferred financing costs. Expenses decreased $0.8 million due to lower interest expense from the new credit facility and unrealized foreign currency gains from re-measurement offset by the write off of the deferred financing fees from the original credit facility.
| Nine months ended Feb 28, 2017 | Feb 29, 2016 | |
|---|---|---|
| Income tax expense (benefit) | $4.0 | $0.1 |
| Effective tax rate including discrete items | 18.1% | (19.5)% |
Income taxes - Our effective tax rate including discrete items for the nine month periods ended February 28, 2017 and February 29, 2016 was 18.1% and (19.5)%, respectively. The change in the effective tax rate, detailed in Note G, is primarily driven by the impact of the US valuation allowance and the deferred tax liability related to intangibles that have an indefinite reversal period and cannot be used to support the deferred tax assets.
Liquidity and Capital Resources
Our cash and cash equivalents totaled $35.6 million as of February 28, 2017, compared with $32.3 million as of May 31, 2016. Marketable securities totaled $1.2 million and $1.7 million as of February 28, 2017 and May 31, 2016, respectively, and consist of an auction rate security. As of February 28, 2017, total principal debt outstanding was $98.8 million and the fair value of contingent consideration payments was $12.6 million.
The table below summarizes our cash flows for the nine months ended February 28, 2017 and February 29, 2016 (in thousands of dollars):
| Cash provided by (used in): | Nine Months Ended Feb 28, 2017 | Feb 29, 2016 |
|---|---|---|
| Operating activities | $36,752 | $26,672 |
| Investing activities | (1,808) | (3,888) |
| Financing activities | (31,416) | (19,167) |
| Effect of exchange rate changes on cash and cash equivalents | (290) | (111) |
| Net change in cash and cash equivalents | $3,238 | $3,506 |
Cash provided by operating activities during the nine months ended February 28, 2017 and February 29, 2016, was primarily the result of net income excluding non-cash items offset by changes in working capital. In the current year period, favorable working capital changes in accounts receivable were partially offset by unfavorable movements in inventories, payables and accrued expenses along with normal operations drove improvement in operating cash by $10.1 million year over year.
The net cash used in investing activities for the current year period consisted of $2.3 million in fixed asset additions offset by proceeds from one of our investments of $0.5 million. The prior year use of cash consisted primarily of $1.9 million of fixed asset additions and $2.0 million in the acquisition of warrants related to the agreement with EmboMedics.
The net cash provided by financing activities is the result of $10.3 million of proceeds from stock option and ESPP activity offset by a $9.9 million payment on earn-out liabilities, net $22.7 million in repayments on long-term debt after the proceeds from the new credit agreement and repayment of the old credit agreement, $1.3 million in deferred financing fees related to the new credit agreement and $7.9 million from the repurchase of common shares. For the year ended February 29, 2016, the net cash provided by financing activities was the result of a $1.9 million of proceeds from stock option and ESPP activity offset by $9.9 million in payments on earn-out liabilities and $11.3 million in repayments on long-term debt.
On November 7, 2016, the Company entered into a Credit Agreement that provides for a $100.0 million senior secured term loan facility and a $150.0 million senior secured revolving credit facility, which includes up to a $20.0 million sublimit for letters of credit and a $5.0 million sublimit for swingline loans.
We believe that our current cash and investment balances, together with future cash generated from operations and our revolving credit facility capacity of up to $150.0 million as of February 28, 2017, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future, we may require additional external financing.
Market risk
As filed, 1,633 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are exposed to market risk from changes in currency exchange rates, as well as interest rate fluctuations on our credit facility and investments that could impact our results of operations and financial position.
We transact sales in currencies other than the U.S. Dollar, particularly the Euro, British pound and Canadian dollar. Approximately 7% of our year to date sales in fiscal 2017 were denominated in foreign currencies. We do not have expenses denominated in foreign currencies at the level of our sales and as a result, our profitability is exposed to currency fluctuations. When the U.S. Dollar strengthens, our sales and gross profit will be negatively impacted. In addition, we have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period, with the offset to changes presented as a component of Other Income (Expenses).
On November 7, 2016, we entered into a Credit Agreement (the "Credit Agreement") which provides for a $100.0 million senior secured term loan facility ("Term Loan") and a $150.0 million senior secured revolving credit facility (the "Revolving Facility", and together with the Term Loan, the "Facilities"). Interest on both the Term Loan and Revolver is based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. In the event of default, the interest rate may be increased by 2.0%. Currently there are no conditions that would result in a material change to our interest rate.
Controls and procedures
As filed, 1,402 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of disclosure controls and procedures
As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting for the fiscal quarter ended February 28, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
AngioDynamics, Inc. and Subsidiaries
Risk factors
As filed, 684 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2016 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-02-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 9 months2016-06-01 to 2017-02-28 | $262.7m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-12-01 to 2017-02-28 | $41.8m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2016-06-01 to 2017-02-28 | $128.9m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2016-12-01 to 2017-02-28 | $43.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2016-06-01 to 2017-02-28 | $133.8m | us-gaap:GrossProfit |
| Research and development | 3 months2016-12-01 to 2017-02-28 | $6.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2016-06-01 to 2017-02-28 | $18.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-12-01 to 2017-02-28 | $5.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2016-06-01 to 2017-02-28 | $24.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-12-01 to 2017-02-28 | $635.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2016-06-01 to 2017-02-28 | $2.2m | us-gaap:InterestExpense |
| Income tax | 3 months2016-12-01 to 2017-02-28 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2016-06-01 to 2017-02-28 | $4.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-12-01 to 2017-02-28 | $2.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2016-06-01 to 2017-02-28 | $17.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-12-01 to 2017-02-28 | $0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2016-06-01 to 2017-02-28 | $0.48 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-12-01 to 2017-02-28 | $0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2016-06-01 to 2017-02-28 | $0.49 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-12-01 to 2017-02-28 | 37,126,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2016-06-01 to 2017-02-28 | 37,068,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2016-06-01 to 2017-02-28 | $36.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2016-06-01 to 2017-02-28 | $2.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2016-06-01 to 2017-02-28 | $7.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-02-28 | $35.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-02-28 | $145.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-02-28 | $704.3m | us-gaap:Assets |
| Current liabilities | At period end2017-02-28 | $50.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-02-28 | $172.6m | us-gaap:Liabilities |
| Long-term debt | At period end2017-02-28 | $92.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-02-28 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-02-28 | $531.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001275187-17-000008. Last ingested by Listed: Nov 4, 2026, 20:24 ET. Listed shows no prices and gives no investment advice.